Key result
Avian hepatitis E virus replicons lacking ORF2 and ORF3 successfully expressed heterologous genes (eGFP, HA-tag, and IBVS1) in LMH cells, demonstrating potential as an RNA vaccine platform.
Why the study?
The study was conducted to evaluate avian hepatitis E virus as an RNA vaccine platform expressing heterologous genes.
Avian hepatitis E virus replicons can successfully express heterologous genes in vitro, demonstrating their potential utility as an RNA vaccine platform.
aHEV replicons may enable new RNA vaccine vectors; hypothesis-generating and requires in vivo validation before any application.
To evaluate avian hepatitis E virus (aHEV) as an RNA vaccine platform, ORF2 of aHEV was replaced by heterologous genes, such as eGFP and HA-tag, in aHEV infectious cDNA clones. eGFP and HA-tag replicons were expressed in LMH cells. To confirm expression of the heterologous protein, ORF2 was replaced with the antigenic S1 gene of IBV. The IBVS1 replicon was expressed in LMH cells. To our knowledge, this is the first investigation showing the potential as a RNA vaccine platform using an aHEV. In the future, it may be used in the development of RNA vaccines against various pathogens.
No takes yet. Share an insight, caveat, or question.
Moon et al. (2021) studied Avian hepatitis E virus. aHEV replicon expressing heterologous genes (eGFP, HA-tag, IBVS1) was evaluated on Expression of heterologous genes in LMH cells. Avian hepatitis E virus replicons lacking ORF2 and ORF3 successfully expressed heterologous genes (eGFP, HA-tag, and IBVS1) in LMH cells, demonstrating potential as an RNA vaccine platform.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: